A major challenge for immunologists has been the development of vaccines able to augment both of humoral and cellular immune responses. One particularly promising approach is the prime-boost strategy, which has been shown to generate high levels of T-cell memory in animal models. In the present study, loaded liposomes were used to determine how does prime-boost strategy would be beneficial for generation of humoral and cellular responses. BALB/c mice were immunized with HIV-1 gp41 (662-683) liposomes and 30 days later they received the booster doseof the same immunogen. HIV-1 gp41 (662-683) specific humoralresponse was evaluated pre-prime, 30days post-prime and 30 days post-boost by ELISA. HIV-1 gp41 (662-683) specific antibodies sharply jumped after boosting by ~40 foldcompared to that generated by priming. Similarly, self-boosting generated considerably HIV-1 gp41 (662-683) specific antigen secreting plasma cells in bone marrow. Overall, the results suggest that self-boosting is very important for generation of specific humoral response for HIV-1 gp41 . This prime-boost strategy shows a promise to induce both of specific-antibodies and specific antibody secreting cells in bone marrowfor weak immunogens like HIV-1 gp41 . Bershteyn, A.; Hanson, M.C.; Crespo, M.P.; Moon, J.J.; Li, A.V.; Suh, H. andIrvine, D.J.(2012): Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J. Control Release, 157(3): 354-365. Buzon, V.; Natrajan, G.; Schibli, D.; Campelo, F.; Kozlov, M.M. and Weissenhorn, W. (2010): Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoSPathog., 6(5): e1000880. Cardoso, R.M.; Zwick, M.B.; Stanfield, R.L.; Kunert, R; Binley, J.M.; Katinger, H.; Burton, D.R. and Wilson, I.A. (2005): Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity, 22(2): 163-173. CDC "Centers for disease control and prevention" (1981): Pneumocystis pneumonia--Los Angeles. Morb.Mortal. Wkly. Rep., 30: 250-252. Coffin, J.; Haase, A.; Levy, J.A.; Montagnier, L.; Oroszlan, S.; Teich, N.; Temin, H.; Toyoshima, K.; Varmus, H.; Vogt, P. and Weiss, R. (1986): What to call the AIDS virus?. Nature, 321(6065): 10. Denner, J. (2011): Towards an AIDS vaccine: the transmembrane envelope protein as target for broadly neutralizing antibodies. Hum. Vaccin., 7(suppl.): 4-9. Donius, L.R.; Cheng, Y.; Choi, J.; Sun, Z. Y.; Hanson, M.; Zhang, M.; Gierahn, T. M.; Marquez, S.; Uduman, M.; Kleinstein, S.H.; Irvine, D.; Love, J. C.; Reinherz, E. L.; and Kim, M. (2016):

No abstract